ABSTRACT
implications for informing primary prevention and/or screening strategies. Future research should assess the clinical utility of such strategies.
INTRODUCTION
Breast cancer (BCa) risk has both genetic and environmental influences. Although the discovery of the BRCA1 and BRCA2 genes and a decade of subsequent clinical research has led to substantial positive impact on the health of women affected with the Mendelian cancer predisposition syndromes conferred by mutations in these genes (1) (2) (3) , the vast majority of BCa genetic risk remains unaccounted for. Building on work suggesting the existence of significant polygenic influences on breast cancer risk (4), recent genome-wide association studies (GWAS) (5-10) and a candidate gene association study (11) have demonstrated that an expanding set of single nucleotide polymorphisms (SNPs) are reproducibly associated with BCa risk in Caucasians and, in some cases, in individuals from other racial/ethnic backgrounds.
As with other complex disorders (12-15), the discovery and validation of these risk SNPs has created an opportunity to explore whether a panel of SNPs can be used to predict disease risk and to assess the clinical relevance of such a panel. In the context of breast cancer, the assessment of disease risk has important clinical implications that can impact decisions about appropriate counseling, screening regimens, and risk reduction strategies (3, (16) (17) (18) (19) (20) . Thus, improvements in risk prediction have the potential to impact clinical care if they are demonstrated to have clinical validity and utility.
For sporadic breast cancer, the Gail Model has been commonly used to produce individual risk estimates. It incorporates individual risk factors including family history (BCa among firstdegree relatives), personal reproductive history (age at menarche and at first live birth), and personal medical history (number of previous breast biopsy examinations and presence of biopsyconfirmed atypical hyperplasia) to estimate personal 5-year and lifetime BCa risk (21) . A projected Gail 5-year risk score (e.g. >1.66%) has implications for BCa primary prevention in the context of identifying a group of women who may benefit from risk reduction with a selective estrogen receptor modulator (SERM) (19, 20) . However, both the discriminatory accuracy of the Gail Model and its calibration in certain populations has been challenged, and uptake of primary prevention strategies amongst physicians caring for women at increased risk for sporadic breast cancer has been modest (22) (23) (24) .
Two recent papers have evaluated the potential impact of adding genetic information from a panel of 7 breast cancer-associated SNPs to the Gail risk model (25, 26) . The first analysis predicted, using receiver operating characteristic curves, that area under the curve (AUC) would improve from 0.607 for the Gail model alone to 0.632 with SNP information added to the Gail model (25) . In an accompanying editorial, Pepe and Janes suggested that ROC curve analysis might not be particularly useful or relevant in this case and that the use of a reclassification tablebased approach could allow the assessment of the fraction of individuals whose risk levels can be meaningfully reclassified (27) . The second study showed that real gains-albeit modest-could be realized in reclassification of risk, under the assumption that the combined model was well calibrated (26) .
Although several papers have began to set expectations for potential clinical gains from adding a multi-SNP panel to Gail Model risk assessment, they have all been theoretical in nature (25, 26, 28) . Here we show, in a nested case-control study from the Women's Health Initiative (WHI) Clinical Trial (29) , that genetic information from a panel of SNPs can be combined with clinical information (i.e., Gail risk) to modestly improve BCa risk estimates in a clinically valid manner in postmenopausal, white women.
METHODS

Description of Case and Control Ascertainment and Sample Handling
We identified all invasive BCa cases that developed between randomization and the originally planned end of the intervention phase of the WHI Clinical Trial (29) that had adequate DNA available for genotyping. We selected one control without a cancer diagnosis for each case, matching on baseline age, self-reported ethnicity, clinical trial participation, years since randomization, and hysterectomy status. Written informed consent was obtained from each woman for her WHI participation. Human investigations were performed after approval by the Fred Hutchinson Cancer Research Center Institutional Review Board. Research subjects had an opportunity to opt in or out of any collaborations involving commercial entities. We restricted our analyses to the subset of these individuals that had consented for commercial use. Of the individuals in the trial, 84 percent provided such consent. The interventions used in the WHI clinical trial are independent of baseline genetic and clinical risk factors by study design, so analyses presented here were not stratified by trial intervention. Due to availability of accurate SNP odds ratios and also Gail model validity, we focused our analyses in this work on non-Hispanic white women in this nested case-control study, representing 87% of the matched cases and controls. Clinical characteristics of these subjects are summarized in Table 1 .
Gail Model and SNP Selection
We used the Gail Model to estimate 5-year risk of BCa based on age, ethnicity, age at menarche, age at first live birth, number of first degree relatives with BCa, and number of previous breast biopsies. We did not have information on biopsy histopathology (i.e., whether atypical hyperplasia was present), so this was coded as "unknown." We scored the subjects using a reimplementation of the current Breast Cancer Risk Assessment Tool (BCRAT) risk calculator from source code downloaded from the National Cancer Institute website (07-Aug-2008).
We selected SNPs to include in the risk classifier that had discovery P values < 5×10
-7 for
SNPs with demonstrated association in genome-wide association studies, to account for multiple hypothesis testing and replication in an independent population. Seven SNPs were found to meet these criteria at the time that the study was initiated (5-8). The 7 SNPs selected from peerreviewed GWAS results have also been reported to be associated with breast cancer with high statistical significance across multiple large sample sets ( Table 2) .
The Composite SNP Risk Score
SNPs were genotyped via a custom chip and/or on the Sequenom platform (Supplemental Methods). To model SNP risk using the 7 selected breast cancer-associated SNPs, we used the estimates of per-allele odds ratios previously reported, as shown in Table 2 . We used a multiplicative model for odds ratio across SNPs, where risk values for each SNP were scaled to have a population average of 1 based on the expected frequencies of the three possible diploid genotypes. Missing genotypes were also assigned a relative risk of 1. None of the model parameters were estimated using data derived from the WHI cohort.
Statistical Analysis
We used logistic regression to estimate odds ratios associated with log-transformed Gail model score and the composite SNP score, separately and combined. The intercept term in the logistic regression was unrestricted, and allows the analysis to adapt to case-control sampling.
The Hosmer-Lemeshow test (30) is typically used to assess model calibration in cohort data. To generate expected numbers of cases and controls, we used logistic regression to refit the intercept for each risk model, holding the coefficient of the log transformed risk score fixed at 1.
This rescales the risk scores to match the actual numbers of cases and controls.
We assessed classification performance using receiver operating characteristic (ROC) curves. We used bootstrap resampling (1000 replicates) to estimate confidence intervals for area under the curve (AUC) as well as differences in AUC. We also evaluated classification accuracy using reclassification tables (31, 32) and quantified differences in classification by "net reclassification improvement" (NRI) (33) . NRI is the sum of proportions of cases moving to a higher risk category minus cases moving to a lower risk category, and proportions of controls moving to a lower risk category minus controls moving to a higher risk category (33) . We again used bootstrap resampling to evaluate confidence intervals for NRI and to determine empirical P values for differences in NRI. We used the same bootstrap samples for each classifier and used paired tests to compare classification performance, to preserve the correlation structure of the classifiers and obtain the most powerful tests. ).
RESULTS
Characteristics of the Women in the Nested Case-Control Cohort
Individual SNP Associations with Breast Cancer
Six of the seven SNPs tested were included on the custom SNP array for the parent Cox, E. Beilharz et al., submitted), all six gave per allele odds ratios in the project dataset that were consistent with those used here from the literature ( Table 2 ). The association was significant, with P < 0.05, for five of the six, while the sixth (rs13281615) yielded P = 0.06. The seventh SNP, rs13387042 was genotyped specifically for this report. The per allele odds ratio estimate for this SNP was 1.16, with 95% confidence interval from 1.05 to 1.29 (P = 0.003).
Hence, there is agreement between SNP associations observed in this cohort and those based on studies in other populations. We did not detect any significant pairwise interactions among the 7
SNPs (21 distinct tests yielded one test with P < 0.05 and none with P < 0.01). However, this study was only powered to detect relatively strong effects.
Independence and Calibration of the SNP Risk Score
We separately tested Gail 5-year absolute risk and the 7-SNP odds ratio estimate for association with BCa incidence by logistic regression with log-transformed predictors. Both were strongly associated (Table 3) . A two-fold increase in Gail risk yields a less-than-two-fold increase in cancer incidence in this cohort, suggesting that Gail risk is not so well calibrated in this dataset, which is consistent with a previous cohort study report from the WHI observational study (23) .
The multiplicative model for SNP risk gives relative risk estimates roughly proportional to observed disease rates. Gail risk and SNP risk were weakly but significantly correlated (r = 0.042, P = 0.02). A combined predictor formed by multiplying the Gail absolute risk by the SNP relative risk was more strongly associated with BCa risk than either component alone. Including logtransformed Gail risk and SNP risk in the model as separate terms in the logistic regression further improves the fit (P = 2.3×10 To visualize the effect of SNP risk for different Gail risk categories in a more clinically intuitive way, we binned the scores into quintiles and evaluated the relationship between SNP risk and BCa odds within each Gail risk stratum ( Figure 1 ). SNP risk is consistently associated with BCa within each stratum. This provides additional evidence that the scores are providing essentially independent information about risk.
To assess calibration of our risk scores, we used the Hosmer-Lemeshow test (30) , which compares expected and observed counts of cases and controls in deciles of risk (Supplemental Table 2 ). As shown in Figure 2 , our SNP risk scores appear to be well calibrated (P = 0.12). Gail risk, however, was not well calibrated (P = 6×10 7 − ), and this lack of calibration carries over to the combined risk score to an intermediate extent (P = 0.001). These results are consistent with our logistic regression results. We did not observe an improvement in calibration in the subset of women with no missing observations for Gail risk factors.
We used linear regression to test whether the log-transformed SNP risk score was predictive of any of the clinical risk factors contributing to the Gail model, while adjusting for case/control status. SNP risk was not significantly correlated with age at menarche (P = 0.96) or age at menopause (P = 0.78), number of first degree relatives with BCa (P = 0.20) or number of previous breast biopsies (P = 0.41). The SNP risk score was most associated with age at first birth (P = 0.10), and this association appeared to be specifically mediated by rs2981582 in FGFR2. This SNP alone gave a stronger signal (P = 0.008) and was the only SNP associated with any Gail clinical component at better than nominal P < 0.05. Considering only controls, age at first birth gave P = 0.03 for association with SNP risk and P = 0.002 for association with rs2981582, and there were no other associations with nominal P < 0.05. Given the modest P values, these results will require replication and validation in other datasets.
Classification Performance of the Combined Risk Score
We assessed classification performance using receiver operating characteristic (ROC)
curves. We compared classification using 5-year Gail absolute risk, SNP risk, and the combined We also evaluated classification accuracy using reclassification tables (30,31) and quantified differences in classification by "net reclassification improvement" (NRI) (32) . While reclassification tables are most clinically intuitive in the context of population-based cohort studies, they still provide useful information here. Specifically, the NRI metric is unaffected by case control sampling. We chose 5-year risk thresholds of 1.5% (for below-average risk) and 2% (for elevated risk) and evaluated reclassification for the combined SNP×Gail score versus Gail risk alone (Table   4 ). The combined risk score tends to push individual risks towards the tails of the risk distribution:
it places 22% fewer cases and 29% fewer controls in the intermediate 1. ). For deciles of Gail risk, NRI is 0.182 (Z = 6.2, P = 2.1×10 -10 ).
The cost effectiveness of a genetic test can be improved by avoiding testing individuals whose status is unlikely to change as a result of the test. Individuals who are far from the classification cut points are unlikely to be reclassified as a result of the test, and as a result, it is less efficient to test them. This effect should be reflected in NRI, because excluding the tails of the risk distribution should result in reclassification of a higher proportion of tested individuals. We evaluated NRI across a grid of possible lower and upper bounds of Gail risk. Excluding women in the tails of the risk distribution resulted in higher NRI (Supplemental Figure 2) . If all women with Gail risk < 1.5% or >2.0% are excluded, then NRI improves to 0.195 (Z = 3.8, P = 8.6×10 -5 ).
Performance in Women with Previous Breast Biopsies
Because women with previous breast biopsies are a group at intermediately elevated risk of BCa in particular need of risk stratification to guide future screening and preventative strategies, we also assessed the impact of the SNP risk score in this subset. Not surprisingly given the loss of an important risk stratifier, the Gail model had an AUC of only 0.514 (95% CI: 0.471 0.561) in − this subset. The combined model had an AUC of 0.571 (95% CI: 0.526 0.614). We also − computed reclassification metrics in the biopsy subset (Supplemental Table 3 ). In this subset, the NRI is 0.175, which is significant despite the smaller number of events (Z = 3.9, P = 4.9×10 5 − ).
Here, classification improved for 14.8% of controls (P = 1.5×10 The calibration and discrimination of the Gail model in the WHI cohort is known to be somewhat worse than has been seen in other large studies (23) . This is likely due to a combination of factors, including higher mammography rates, differences in age distributions, and (4) the area under the ROC curve, which is the probability that a predicted risk for an individual with an event is higher than for an individual without an event, has minimal direct clinical relevance (34) . Therefore, we utilized reclassification tables (30, 31) to calculate a net reclassification improvement (32) which is a more helpful measure of the potential impact of the combined Gail plus SNP test (27, (31) (32) 34) . NRI is a relatively new statistic, but has gained increasing acceptance as an important part of the evaluation of new biomarkers and risk stratifiers (34, 35) . This analysis demonstrated a statistically significant improvement in classification (NRI = 0.085; P = 1.0×10 -5 We also evaluated whether it might be possible to obtain better test performance by focusing on a subset of women at particularly high risk-those with previous breast biopsies (36, 37) . Although this analysis was limited by the lack of pathology results to allow identification of those with more serious histopathologies such as atypical hyperplasia, we pursued similar ROC curve and reclassification The major finding from this study is the demonstration that genetic risk information may be combined multiplicatively with Gail risk scores to improve BCa risk estimation in postmenopausal white women. This finding is based both on the observation that patient BCa risk may be accurately estimated by combining published SNP risk estimates, and also the observation that correlation between SNP risk scores and Gail scores for individuals is weak, allowing patient BCa risk to be more accurately estimated by combining SNP and Gail risks multiplicatively. Thus, the present study supports the claim that the combined risk estimation model approach has clinical validity in the broad sense in postmenopausal, white women.
Our analysis has not addressed clinical utility. The use of improved risk models, such as the one described here, may benefit the public health if shown to have clinical utility when combined with optimal individualized screening and risk reduction strategies. A previous evaluation of utility considered an unselective "all comers" strategy for SNP testing (26) . The results of our analysis suggest that, as utility is sensitive to how a test is targeted, it may be wise to focus the application of SNP genotyping for breast cancer risk on women at intermediate risk as
measured by the Gail model. Such a strategy clearly boosts reclassification performance in this study. Future research should assess performance in population-based cohorts and ultimately take the next step and address whether reclassification improvement can be translated into improved prevention and/or screening outcomes in the clinic. 
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Supplemental Methods and Data
Supplemental Methods
Genotyping
The samples were genotyped on custom oligonucleotide arrays across 9039 SNPs selected from previous genome-wide association studies, including 6 of the 7 replicated breast cancer association loci. Pair-wise identity-by-state analysis identified three apparent sibling pairs, and we excluded one member of each pair from analyses. The average concordance across duplicate samples included for quality control was 99.8%, and the breast cancer loci all had call rates above 99%. We used principal components analysis to model population structure, and results were generally consistent with self-reported ethnicity.
Separately, samples with sufficient available DNA were genotyped across all 7 breast cancer loci by Sequenom on the MassArray platform, along with 16 additional SNPs for quality control that had also been genotyped on the arrays. We designed two assays in opposing orientations for each of the breast cancer SNPs, and these were carried out in separate multiplexes. We used whole genome amplification (WGA) for roughly 70% of the samples and observed a reduction in genotyping quality for the WGA samples as compared to the genomic DNA samples. While most WGA samples had satisfactory performance, a subset showed a combination of elevated missing data rates, reduced heterozygosity, and inconsistencies with the array-based genotype data. As a result, we excluded Sequenom data for any sample that had more than one inconsistency with a corresponding array-based genotype. This led to exclusion of Sequenom genotype data for 121 samples, which were almost equally distributed across cases and controls.
We scored consensus genotypes for rs13387042 by combining calls from the two Sequenom assays, scoring conflicting genotypes as missing. Concordance across the two assays was 97%, and the resulting call rate for the consensus genotypes was 96.8% across samples that had not been excluded for lack of DNA or poor data quality. While these assays performed relatively poorly, the consensus of the two assays should still be very accurate, and missing consensus calls were not differentially distributed across cases and controls (P = 0.27, χ 2 test).
The Composite SNP Risk Score
Based on a log-additive risk model, the three genotypes AA, AB, and BB for a single SNP The two approaches give similar results when absolute risk is estimated over short time intervals (such as 5 years) and differences become apparent only at high risk levels (Supplemental Figure   1 ). For this study, we used the second estimation approach. Thus, the formula for our combined SNP×Gail absolute risk score is:
where Gail is the Gail absolute risk score, and SNP1..7 are relative risk scores for the individual SNPs, each scaled to have a population average of 1.
Supplemental Data
Genotyping Performance Summary
Supplemental Table 1 summarizes genotyping results for the 7 BCa associated SNPs.
We excluded from analyses 27 samples that had more than 2 missing genotypes out of these 8
SNPs; for the remaining samples included in our analyses, 90% had complete data for the 8
SNPs. The lower call rate for rs13387042 is primarily a result of the samples that could not be genotyped due to insufficient DNA. There were no apparent deviations from Hardy-Weinberg equilibrium.
Estrogen Receptor Focused Analysis
A previous study had shown that the Gail model is more effective at predicting estrogen receptor positive (ER+) than ER negative (ER-) tumors in the WHI cohort (S1), and most of the individual SNPs have shown stronger associations with ER+ than ER-tumors (S2). We used logistic regression to measure association for the risk scores by tumor subtype (Supplemental Table 3 ). Results for ER+ tumors were similar to results for all invasive breast cancers. Gail risk and the combined risk score were not predictive for ER-tumors; SNP risk by itself still had evidence for association (P = 0.04), but the effect size was poorly defined due to the smaller sample size. We used bootstrap resampling to assess significance of differences in AUC for risk scores as a function of tumor receptor status (Supplemental Table 4 ). Gail and combined risk scores had substantially larger AUC for ER+ than ER-tumors (empirical P < 0.001 in both cases).
For SNP risk, the difference in AUC for ER+ versus ER-tumors was borderline significant (95% CI: 0.01 0.10, two-sided − P = 0.02). AUC for ER+ tumors was also significantly larger than for all invasive cancers for both Gail score (empirical P = 0.02) and the combined score (empirical P = 0.02), though these differences were small.
We investigated using ER-specific odds ratios to form separate ER-positive and ERnegative versions of the SNP risk score. We compared performance of these scores to the general SNP risk score by AUC. Bootstrap confidence intervals for the difference in AUC crossed zero for both receptor status subtypes (Supplemental Table 5 ). While we were unable to conclusively demonstrate improved classification with the available sample sizes, prediction of ER-cancers appeared most likely to improve (one-sided P = 0.05).
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